Close Menu

J&J

The UK is partnering with pharmaceutical companies to sequence and analyze DNA samples from UK Biobank participants.

The project is funded with £50 million from the UK government, £50 million from the Wellcome Trust, and £100 million from four pharmaceutical firms.

Veracyte plans to launch a new version of its Percepta test and present data for a nasal swab lung cancer diagnostic this year.

It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.

This week's news includes the College of American Pathologists, Johnson & Johnson Innovation, Myriad Genetics, and Merck.

As part of the collaboration, Johnson & Johnson will build a lung cancer center at Boston University and build upon programs linked to cancer research.


The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.

The firm’s emphasis on automation has yielded Dx products for blood banks, assays for HIV and acute kidney injury, and flexible diagnostic test systems that can adapt to labs’ changing needs.

The companies will work to develop an affordable, portable, and easy-to-use HIV quantitative viral load test using Cue's Lab-In-A-Box MDx platform.

Johnson & Johnson announced that it would be cutting about 3,000 jobs from its medical devices section.

Pages

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.